Drawing for EBSALVE

USPTO serial 77438646

EBSALVE

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
Examiner
Law office
NEW APPLICATION PROCESSING

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EBSALVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jand Ungaro

JANE UNGARO PFIZER INC.150 EAST 42ND STREETTRADEMARK DEPARTMENT 5HT FLOORNEW YORK, NY 10017

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, gynecological, hematologic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncological, ophthalmological, psychiatric, respiratory, sleep, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of allergies, erectile dysfunction, sexual dysfunction, obesity, pain, and HIV/AIDS; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparationsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 13, 2008MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
May 13, 2008ABN1ABANDONMENT - EXPRESS MAILED
May 12, 2008EXARTEAS EXPRESS ABANDONMENT RECEIVED
Apr 8, 2008MPMKNOTICE OF PSEUDO MARK MAILED
Apr 7, 2008NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance